Ankle-Brachial Index and cardiovascular events in atrial fibrillation: The ARAPACIS study

Thrombosis and Haemostasis

Volumn 115, Issue 4, 2016, Pages 856-863

  Violi, Francesco ^a   Davì, Giovanni ^b   Proietti, Marco ^c   Pastori, Daniele ^a   Hiatt, William R ^d   Corazza, Gino Roberto ^e   Perticone, Francesco ^f   Pignatelli, Pasquale ^a   Farcomeni, Alessio ^a   Vestri, Anna Rita ^a   Lip, Gregory Y H ^c,g   Basili, Stefania ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g AALBORG UNIVERSITY   (Denmark)

Author keywords

ABI; ARAPACIS; Atrial fibrillation; Myocardial infarction; Vascular events

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; CLINICAL TRIAL; ITALY; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; RISK; SURVIVAL ANALYSIS; VASCULAR DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; VASCULAR DISEASES;

EID: 84964732950     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-07-0612     Document Type: Article

References (37)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Stat-istics-2015 Update: A Report From the American Heart Association. Circulation 2015; 131: e29-e322.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Med Assoc 2001; 285: 2370–2375.
3. Polimeni L, Perri L, Saliola M, et al. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med 2010; 5: 91–94.
4. Chao TF, Huang YC, Liu CJ, et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 2014; 11: 1941–1947.
5. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455–2461.
6. Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295–304.
7. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardio-graphic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998; 31: 1622–1626.
8. Perlstein TS, Creager MA. The ankle-brachial index as a biomarker of cardiovascular risk: it’s not just about the legs. Circulation 2009; 120: 2033–2035.
9. Violi F, Lip GY, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med 2012; 7: 213–218.
10. Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 2012; 126: 2890–2909.
11. Grenon SM, Gagnon J, Hsiang Y. Video in clinical medicine. Ankle-brachial index for assessment of peripheral arterial disease. N Engl J Med 2009; 361: e40.
12. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053–2061.
13. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. J Am Med Assoc 2008; 300: 197–208.
14. Raparelli V, Proietti M, Napoleone L, et al. Asymptomatic peripheral artery disease and antiplatelet management. Vasa 2014; 43: 309–325.
15. Violi F, Daví G, Hiatt W, et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol 2013; 62: 2255–2256.
16. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 2005; 25: 1463–1469.
17. Jones WS, Patel MR, Rockman CB, Guo Y, Adelman M, Riles T, Berger JS. Association of the ankle-brachial index with history of myocardial infarction and stroke. Am Heart J 2014; 167: 499–505.
18. Raparelli V, Proietti M, Buttà C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med 2014; 9: 861–870.
19. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104–123.
20. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263–272.
21. Violi F, Daví G, Hiatt W, et al. Reply: ankle-brachial index in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2014; 63: 1457–1458.
22. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.
23. Special report from the National Institute of Neurological Disorders and Stroke Classification of cerebrovascular diseases III. Stroke 1990; 21: 637–676.
24. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
25. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
26. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
27. Kamp O, Verhorst PM, Welling RC, et al. Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation. Eur Heart J 1999; 20: 979–985.
28. Proietti M, Calvieri C, Malatino L, et al. Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. Atherosclerosis 2015; 238: 350–355.
29. Criqui MH, McClelland RL, McDermott MM, et al. The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 56: 1506–1512.
30. Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014; 35: 242–249.
31. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. J Am Med Assoc Intern Med 2014; 174: 107–114.
32. Roldán V, Marín F, Fernández H, et al. Renal impairment in a „real-life“cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013; 111: 1159–1164.
33. Soliman EZ, Lopez F, O’Neal WT, et al. Atrial Fibrillation and Risk of ST-Segment Elevation versus Non-ST Segment Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2015; 131: 1843–1850.
34. Vermond RA, Van Gelder IC, Crijns HJ, Rienstra M. Does Myocardial Infarction Beget Atrial Fibrillation and Atrial Fibrillation Beget Myocardial Infarction? Circulation 2015; 131: 1824–1826.
35. Gamra H, Murin J, Chiang CE, et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 2014; 107: 77–87.
36. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638–645.e4.
37. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 3: e000697.